newdrugapprovals.org
FDA approves novel treatment Oxbryta (voxelotor) to target abnormality in sickle cell disease
Today, the U.S. Food and Drug Administration granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and …